<code id='FF0D7D02FB'></code><style id='FF0D7D02FB'></style>
    • <acronym id='FF0D7D02FB'></acronym>
      <center id='FF0D7D02FB'><center id='FF0D7D02FB'><tfoot id='FF0D7D02FB'></tfoot></center><abbr id='FF0D7D02FB'><dir id='FF0D7D02FB'><tfoot id='FF0D7D02FB'></tfoot><noframes id='FF0D7D02FB'>

    • <optgroup id='FF0D7D02FB'><strike id='FF0D7D02FB'><sup id='FF0D7D02FB'></sup></strike><code id='FF0D7D02FB'></code></optgroup>
        1. <b id='FF0D7D02FB'><label id='FF0D7D02FB'><select id='FF0D7D02FB'><dt id='FF0D7D02FB'><span id='FF0D7D02FB'></span></dt></select></label></b><u id='FF0D7D02FB'></u>
          <i id='FF0D7D02FB'><strike id='FF0D7D02FB'><tt id='FF0D7D02FB'><pre id='FF0D7D02FB'></pre></tt></strike></i>

          Home / knowledge / knowledge

          knowledge


          knowledge

          author:explore    Page View:24989
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In